Antibodies to OPGL

Details for Australian Patent Application No. 2002320157 (hide)

Owner Amgen Inc. Amgen Fremont Inc.

Inventors Corvalan, Jose R.; Boyle, William J.; Davis, Geoffrey C.; Martin, Francis H.

Agent Shelston IP

Pub. Number AU-B-2002320157

PCT Number PCT/US02/20181

PCT Pub. Number WO2003/002713

Priority 60/301,172 26.06.01 US

Filing date 25 June 2002

Wipo publication date 3 March 2003

Acceptance publication date 16 October 2008

International Classifications

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 19/08 (2006.01) Drugs for skeletal disorders

A61P 19/10 (2006.01) Drugs for skeletal disorders

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 37/02 (2006.01) Drugs for immunological or allergic disorders

C07D 475/10 (2006.01) Heterocyclic compounds containing pteridine ring systems

C07K 16/24 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12P 21/08 (2006.01) Preparation of peptides or proteins - Monoclonal antibodies

Event Publications

16 January 2003 Complete Application Filed

  Priority application(s): 60/301,172 26.06.01 US

15 May 2003 Application Open to Public Inspection

  Published as AU-B-2002320157

4 October 2007 Assignment before Grant

  Amgen Inc.; Abgenix, Inc. The application has been assigned to Amgen Inc.; Amgen Fremont Inc.

16 October 2008 Application Accepted

  Published as AU-B-2002320157

12 February 2009 Standard Patent Sealed

23 December 2010 Extension of Term of Standard Patents

  Amgen Inc.; Amgen Fremont Inc. The earliest first regulatory approval date provided by the patentee 07 Jun 2010 For the goods PROLIA denosumab Applications Accepted The following application(s) for Extension of Term have been accepted under Section 74. Notice of opposition under Section 75(1) to the undermentioned application(s) for an extension of term may be filed at the Patent Office within the prescribed time.

20 January 2011 Extension of Term of Standard Patents

  Amgen Inc.; Amgen Fremont Inc. The earliest first regulatory approval date provided by the patentee 07 Jun 2010 For the goods PROLIA denosumab Address for service in Australia: Shelston IP Level 21 60 Margaret Street Sydney NSW 2000

16 June 2011 Extension granted

  Amgen Fremont Inc.; Amgen Inc. Extensions of Term of Standard Patents Extension of Term of a Standard Patent relating to Pharmaceutical Substances Extensions granted The earliest first regulatory approval date provided by the patentee 07 Jun 2010 For the goods PROLIA denosumab Extension of Term of patent pursuant to Section 77 expires on 07 Jun 2025

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002320158-ORGANIC LIGHT-EMITTING DEVICES WITH BLOCKING AND TRANSPORT LAYERS

2002320156-RISK EVALUATION SYSTEM AND METHODS